In the FHSXMU/SPPH cohort, significant differences in pathological grade, MGMT promoter status, IDH genotype, survival status, tumor volume, and survival outcome (HR: 2.553, 95%CI: [1.226–5.315]) between the two subtypes (P < 0.05). This evidence concerns the gene MGMT and neoplasm.